Adaptive designs for clinical trials assessing biomarker-guided treatment strategies

por Wason, J, Marshall, A, Dunn, J, Stein, R C, Stallard, N
Publicado 2014

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.

por Stein, R. C., Dowsett, M., Hedley, A., Gazet, J. C., Ford, H. T., Coombes, R. C.
Publicado 1990

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.

por Stein, R. C., Dowsett, M., Cunningham, D. C., Davenport, J., Ford, H. T., Gazet, J. C., von Angerer, E., Coombes, R. C.
Publicado 1990

Predictors of ovarian reserve in young women with breast cancer

por Lutchman Singh, K, Muttukrishna, S, Stein, R C, McGarrigle, H H, Patel, A, Parikh, B, Groome, N P, Davies, M C, Chatterjee, R
Publicado 2007

The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]

por Stein, R. C., Malkovska, V., Morgan, S., Galazka, A., Aniszewski, C., Roy, S. E., Shearer, R. J., Marsden, R. A., Bevan, D., Gordon-Smith, E. C.
Publicado 1991

Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial

por Pinder, S E, Campbell, A F, Bartlett, J M S, Marshall, A, Allen, D, Falzon, M, Dunn, J A, Makris, A, Hughes-Davies, L, Stein, R C
Publicado 2017

Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer

por Conefrey, C., Donovan, J.L., Stein, R.C., Paramasivan, S., Marshall, A., Bartlett, J., Cameron, D., Campbell, A., Dunn, J., Earl, H., Hall, P., Harmer, V., Hughes-Davies, L., Macpherson, I., Makris, A., Morgan, A., Pinder, S., Poole, C., Rea, D., Rooshenas, L.
Publicado 2020